Login to Your Account

Taking giant 'STEP ONE,' Viacyte absorbs assets of Janssen Betalogics

By Marie Powers
Staff Writer

Thursday, February 4, 2016

The mouse swallowed the cat, so to speak. Although its pluripotent stem cell-derived islet replacement candidate, VC-01, is still in the first-in-human study known as STEP ONE, Viacyte Inc. showed that it's gained clout in the diabetes field.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription